Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.

J Immunother Cancer · 2026 · PMC13289407 · PMID 42285608

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep=0.09so close (0.05 < p ≤ 0.1)

While OX40 expression trended higher in the BLINA-treated groups, this did not reach statistical significance (p=0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.